Lead Plaintiff Opportunity in Jasper Therapeutics Securities Fraud Lawsuit: What Investors Need to Know

Jasper Therapeutics Securities Fraud Lawsuit: Join the Class Action

On November 14, 2025, the Rosen Law Firm, a prominent investor rights law firm, issued a reminder to investors of Jasper Therapeutics, Inc. (NASDAQ: JSPR). If you purchased shares of this company between November 30, 2023, and July 3, 2025, you may have the opportunity to participate in a class action lawsuit against the company. The deadline to apply as a lead plaintiff is rapidly approaching on November 18, 2025.

Overview of the Class Action

The class action lawsuit concerns allegations of securities fraud by Jasper Therapeutics. Investors who acquired shares during the designated time frame might be entitled to compensation due to misleading statements made by the company's management.

What Investors Should Know

If you are an investor in Jasper Therapeutics and think you may have been affected by this situation, take note: participating in this class action can be an avenue to recover potential losses without needing to pay any upfront out-of-pocket fees. The Rosen Law Firm operates on a contingency fee basis, meaning that if you do not win the case, you do not owe any fees.

Steps to Join

To join the class action lawsuit, you can visit the Rosen Law Firm's webpage dedicated to this case here. Alternatively, you can reach out to Phillip Kim, Esq. via toll-free number 866-767-3653, or via email at [email protected]. It is vital to act quickly, particularly if you want to serve as the lead plaintiff, as you must file your motion with the court by the upcoming deadline.

Details of Allegations

The crux of the allegations suggests that the defendants made several false or misleading statements about Jasper Therapeutics' operational practices and product prospects. Specific claims include:
1. The company lacked adequate controls to ensure that its third-party manufacturing partners were compliant with cGMP regulations, potentially jeopardizing clinical trial results.
2. This failure heightened the risk of unpredictable study outcomes, adversely affecting both the regulatory approval and market potential of their flagship product, briquilimab.
3. The misleading public statements led to an inflated perception of the company's financial health and market viability.

When the actual circumstances of the company’s situation were made public, many investors began to suffer significant losses. The lawsuit aims to address these damages and seek compensation for all affected parties who were misled.

Importance of Selecting Qualified Counsel

Rosen Law Firm emphasizes the importance of choosing experienced legal counsel when participating in a class action lawsuit. Many firms may advertise such opportunities but lack the necessary experience or results in litigation. The firm prides itself on having a proven track record, boasting significant settlements and a history of successful recoveries for investors.

Their reputation is backed by their past achievements, including the largest securities class action settlement against a Chinese company at the time and recognition as a top firm in class action settlements over the years.

Conclusion

Investors in Jasper Therapeutics should take this alert from the Rosen Law Firm seriously. The opportunity to join the class action lawsuit could mean the difference in recovering some or all of the losses incurred due to misleading statements from the company. Do not delay; ensure that you consider your options before the looming lead plaintiff deadline. Remain vigilant by following the firm for updates on social media, including on LinkedIn, Twitter, and Facebook.

For More Information

For further inquiries or to stay informed about this case, please reach out to the Rosen Law Firm through their contact details provided above. With their experience and proven success in securities law, they may be able to help you navigate this challenging situation successfully.